ProCE Banner Activity

Targeting LAG-3 to Potentiate Antitumor Immune Activity: Expert Guidance on Molecular Function and Clinical Application

Slideset Download
Download these slides from a live workshop series to learn more about LAG-3 as the latest validated immune checkpoint therapeutic target, evidence on the first approved LAG-3 therapy, relatlimab, and the many investigational agents targeting LAG-3 across multiple tumor types.

Released: March 23, 2022

Expiration: March 22, 2023

No longer available for credit.

Share

Faculty

Evan J. Lipson

Evan J. Lipson, MD

Associate Professor of Oncology
Melanoma and Cancer Immunology Programs
Bloomberg-Kimmel Institute for Cancer Immunotherapy
Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Tian Zhang

Tian Zhang, MD, MHS

Associate Professor
Genitourinary Oncology and Multi-Disease Precision Oncology Programs
Division of Hematology and Oncology
Department of Internal Medicine
UT Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
Dallas, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Bristol Myers Squibb

Faculty Disclosure

Primary Author

Evan J. Lipson, MD

Associate Professor of Oncology
Melanoma and Cancer Immunology Programs
Bloomberg-Kimmel Institute for Cancer Immunotherapy
Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Tian Zhang, MD, MHS

Associate Professor
Genitourinary Oncology and Multi-Disease Precision Oncology Programs
Division of Hematology and Oncology
Department of Internal Medicine
UT Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
Dallas, Texas